Discover the Best Digital Biology Tools

Recursion Pharmaceuticals operates one of the world's largest proprietary biological and chemical datasets, combining high-throughput wet-lab experiments with advanced machine learning to map biological relationships at scale. The Recursion OS platform integrates automated cell biology experiments, large-scale phenomics imaging, and foundation models to identify drug candidates faster than traditional approaches. Pharmaceutical companies and biotech firms use Recursion's platform to discover novel therapeutic targets, repurpose existing compounds, and advance preclinical candidates across oncology, rare diseases, and infectious disease. The platform has generated over 36 petabytes of proprietary biological data, enabling AI models trained on billions of experimental data points. Recursion's key differentiator is its closed-loop system where wet-lab experiments continuously feed AI models, which in turn design the next round of experiments. The company has multiple clinical-stage programs and strategic partnerships with Roche-Genentech, Bayer, and others valued at over $1 billion in total deal value.

Insilico Medicine is a clinical-stage AI-driven drug discovery company that has built an integrated Pharma.AI platform spanning target identification (PandaOmics), molecular generation (Chemistry42), and clinical trial outcome prediction (InClinico). The platform leverages generative adversarial networks, reinforcement learning, and transformer architectures to design novel drug candidates from scratch. Pharma partners and internal pipeline teams use the platform to compress drug discovery timelines from years to months. Insilico's lead program, ISM001-055 for idiopathic pulmonary fibrosis, was designed entirely by AI — from target identification to molecule generation — and advanced to Phase II clinical trials, making it one of the first fully AI-designed drugs in clinical development. What sets Insilico apart is its end-to-end AI capability covering the full drug discovery pipeline. The company holds over 30 active pipeline programs across fibrosis, oncology, and immunology, with strategic partnerships including Sanofi and additional global pharma collaborators. Its Chemistry42 module can generate novel molecular structures optimized for multiple drug-like properties simultaneously.

AlphaFold is a revolutionary AI system developed by Google DeepMind that predicts 3D protein structures from amino acid sequences with accuracy comparable to experimental methods like X-ray crystallography and cryo-EM. AlphaFold 2 solved the 50-year protein folding problem and AlphaFold 3 extended predictions to complexes including proteins, DNA, RNA, and small molecules. Researchers across academia, pharma, and biotech use the AlphaFold Protein Structure Database (maintained with EMBL-EBI) to access over 200 million predicted structures covering nearly every known protein. This has accelerated research in drug design, enzyme engineering, and understanding disease mechanisms, saving scientists years of experimental structure determination. AlphaFold's impact is unmatched in computational biology — it earned the 2024 Nobel Prize in Chemistry. The open-access database and code have been cited in over 20,000 research papers. AlphaFold 3's ability to model protein-ligand interactions makes it a foundational tool for structure-based drug design.